[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nemours Children's Clinic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":621},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,46,70,96,118,146,168,192,222,248,274,298,326,348,388,424,448,467,487,510,537,561,574,596],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054167","comparative-outcomes-related-to-delivery-room-cord-milking-in-low-resourced-kountries--preterm-100054167",false,"NCT06240715","Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries- PreTerm","A Cluster Randomized Clinical Trial of Umbilical Cord Milking Compared to Early Cord Clamping in Preterm Infants Who Are Non-vigorous at Birth","CORDMILK-PT","Inclusion Criteria:\n\n* Preterm infants born between 30 0\u002F7 weeks to 34 6\u002F7 weeks of gestation\n* Non-vigorous at birth\n\nExclusion Criteria:\n\n* Infants with congenital malformation\n* Major chromosomal abnormalities\n* Complete placental abruption\u002Fcutting through the placenta at the time of delivery\n* Cord conditions (umbilical knots, inadequate cord length, cord rupture, non-reducible nuchal cord)\n* Mono-chorionic twins,\n* Twins with no information on amnion\u002Fchorion\n* Multiple gestation \\>2","ALL","0 Minutes","10 Minutes",{"count":21,"type":22},800,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this multicenter, cluster-randomized, crossover trial is to determine if umbilical cord milking compared to early cord clamping will reduce in-hospital mortality in non-vigorous preterm infants born between 30 weeks and 34 weeks of gestation.",[28,29],"Preterm","Infant Death",[28,31,32],"Umbilical cord milking","Placental transfusion","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2024-07-01",{"date":41,"type":22},"2027-03-30",{"name":43,"class":44},"Nemours Children's Clinic","OTHER",9,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100529314","transdisciplinary-care-for-young-adults-with-type-1-diabetes-100529314","NCT06172166","Transdisciplinary Care for Young Adults With Type 1 Diabetes","Transdisciplinary Care for Young Adults With Type 1 Diabetes Transitioning to Adult Healthcare","TCT","Inclusion Criteria:\n\n* Diagnosed with type 1 diabetes for at least 6 months\n* Approaching their last visit with their pediatric type 1 diabetes healthcare provider. They will have their final visit with their pediatric T1D provider within about a month of enrollment in the study.\n* English fluency\n\nExclusion Criteria:\n\n* Another systemic chronic medical illness except celiac disease, autoimmune thyroiditis, microalbuminuria, hypertension, or well-managed asthma\n* Developmental disability limiting independent living\n\nWe are recruiting eligible individuals through Nemours and remotely.","17 Years",{"count":56,"type":22},80,[25],"The incidence of type 1 diabetes (T1D) is increasing globally with the most substantial increases occurring in the youngest age groups. A growing number of youths with T1D must therefore transition their healthcare from pediatric to adult T1D care settings as they approach young adulthood. This healthcare transition introduces many challenges because it coincides with a developmental period that is fraught with social, financial, residential, school\u002Fwork and other changes\u002Fdemands. Thus, it is not surprising that young adults (YA) with T1D are at risk for suboptimal glycemic levels, the development of diabetes-related complications, and psychosocial issues such as depression, anxiety, and disordered eating. Yet, few evidence-based interventions to assist YA with T1D with this complex healthcare transition exist.\n\nIn this study, we are testing the feasibility, acceptability, and initial efficacy of a novel transdisciplinary model of care (Transdisciplinary Care for Transition; TCT) in which a diabetes nurse educator, psychologist, and transition navigator (case manager) co-deliver transitional care. TCT addresses the psychological and systems barriers to transition and aims to improve outcomes via better assessment of YA needs and resources, better cross-discipline and YA-provider communication, and better collaboration with YA to resolve problems that cross pediatric and adult healthcare settings.\n\nWe will recruit 80 YA with T1D during their final visit in pediatric T1D specialty care to participate in a pilot randomized controlled trial during which we will randomize YA to a standard care control group (SCC) or to receive three TCT visits during the 6 months post discharge from pediatric T1D care. In SCC, participants will transition to adult T1D care as usual per their clinic's standard transition procedures.\n\nAll study procedures can be completed remotely. This includes enrollment, study evaluations, and TCT visits for those randomized to TCT. Thus, we are recruiting individuals from across the United States.\n\nAim 1: Examine the feasibility, acceptability, and fidelity of TCT in YA with T1D.\n\nAim 2: Examine the preliminary efficacy of TCT versus SCC on YA HbA1c, transition readiness and success, and continuity of care and explore for an effect on diabetes distress and acute care utilization.",[60],"Type 1 Diabetes","2026-06-24",{"date":63,"type":37},"2026-06-29",{"date":65,"type":37},"2024-04-17",{"date":67,"type":22},"2028-04-30",{"name":43,"class":44},2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100563491","personalized-mobile-health-platform-to-promote-physical-activity-in-adolescents-and-young-adults-with-cystic-fibrosis-100563491","NCT06616857","Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis","NUDGE","Inclusion Criteria:\n\n1. 13-25 years old\n2. Has a verified CF diagnosis or CF-related disorder\n3. Medically stable (i.e., FEV1\\>30%, not experiencing a CF-related exacerbation)\n4. Speaks and reads English\n\nExclusion Criteria:\n\n1. Have a comorbidity limiting PA participation (e.g., neurological condition)\n2. Have a significant cognitive impairment that interferes with study completion\n3. Have any oxygen, CPAP or BiPAP requirement","13 Years","25 Years",{"count":80,"type":22},30,[25],"The goal of this clinical trial is to help adolescents and young adults between the ages of 13-25 with Cystic Fibrosis (CF), medically stable, able to speak and read English, and are not experiencing a CF - related exacerbation, who are already active to remain, or gradually encourage them to increase their levels of physical activity\n\nParticipants will be asked to utilize a smartphone program, called NUDGE that we have developed. NUDGE is a chatbot with evidence-based features known to help teens make progress toward health goal:\n\n* Set and review goals\n* Self-monitor progress\n* Provide feedback on goal attainment\n* Revise future goals",[84],"Cystic Fibrosis (CF)",[86],"physical activity","2026-06-22",{"date":89,"type":37},"2026-06-23",{"date":91,"type":37},"2025-02-18",{"date":93,"type":22},"2026-12",{"name":43,"class":44},1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":95},"100468755","empowering-adolescents-and-young-adults-with-sickle-cell-disease-as-partners-in-treatment-decision-making-empower-aya-100468755","NCT05383911","Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)","EMPOWER-AYA","Inclusion Criteria:\n\n* Patients diagnosed with SCD ages 15-25 years receiving treatment at Nemours and their caregivers will be included. Patients must be deemed candidates for initiation of one or more disease-modifying therapies by their SCD healthcare provider.\n* Nemours SCD healthcare providers will also be included.\n* English language fluency is a requirement for all participants.\n\nExclusion Criteria:\n\n* Patients\u002F caregivers who previously participated in usability testing of the intervention will be excluded.\n* Patients will also be excluded if they have history of seizures, if their medical status or cognitive functioning preclude completion of interviews, or if no legal guardian is available to provide consent (for patients \\\u003C 18 years).\n* Providers still completing training will be excluded.","15 Years",{"count":105,"type":22},68,[25],"This study will evaluate the acceptability, feasibility, and preliminary efficacy of a shared decision making intervention for adolescents and young adults (AYAs) with sickle cell disease (SCD). 60 AYAs with SCD ages 15-25 and their caregivers and 8 SCD providers will participate in the pilot pragmatic trial. AYAs, caregivers, and providers will be recruited from Nemours Children's Hospital, Delaware (NCH-DE), Nemours Children's Hospital in Orlando, FL (NCH-ORL), and Nemours Children's Health at Wolfson Children's Hospital in Jacksonville, FL (NCH-JAX). NCH-DE participants (n=30) will receive the SDM intervention including a virtual reality patient health education component, whereas NCH-ORL and NCH-JAX participants (n=30) will receive the SDM intervention with standard patient education materials (print, video). SCD providers will be trained to use the toolkit components and will introduce decision aids during an outpatient clinic visit for AYAs who are candidates for one or more disease-modifying therapies.",[109],"Sickle Cell Disease","2026-06-15",{"date":112,"type":37},"2026-06-16",{"date":114,"type":37},"2024-11-26",{"date":116,"type":22},"2027-06-30",{"name":43,"class":44},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":125,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},"100461872","testing-esccip-an-ehealth-psychosocial-intervention-for-english-and-spanish-speaking-parents-of-children-with-cancer-100461872","NCT05294302","Testing eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer","A Randomized Controlled Trial of eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer","Inclusion Criteria:\n\n* Participants must be the parent or primary caregiver of a child (ages 0 - 18 years old) diagnosed with cancer.\n* Participants must be able to speak and read English or Spanish.\n* Participants must have access to the internet through a computer or mobile device (e.g., smartphone, tablet).\n\nExclusion Criteria:\n\n* PCCC are ineligible to participate if their child is not expected to live longer than six months from the time of potential recruitment",true,{"count":127,"type":22},350,[25],"It is critical to provide accessible evidence-based psychosocial support to parents and caregivers of children with cancer (PCCC) in order to mitigate individual and family-level psychosocial risks. This effectiveness trial evaluates an eHealth intervention for English- and Spanish-speaking (PCCC) with study endpoints focused on decreasing negative psychosocial sequelae (acute distress, posttraumatic stress, and anxiety) and improving coping abilities (coping self-efficacy, cognitive coping strategies). The long-term goal of this research program is to sustain and disseminate an effective, scalable, high-reach, and cost-effective intervention to provide crucial support to PCCC across the pediatric cancer trajectory.",[131],"Pediatric Cancer",[133,134,135,136],"eHealth","pediatric cancer","parents","psychosocial intervention","2026-06-03",{"date":139,"type":37},"2026-06-05",{"date":141,"type":37},"2023-04-14",{"date":143,"type":22},"2026-12-31",{"name":43,"class":44},3,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100530849","continuous-passive-motion-device-for-children-with-arthrogryposis-100530849","NCT06192134","Continuous Passive Motion Device for Children With Arthrogryposis","Inclusion Criteria:\n\n* Children with arthrogryposis\n* Children between 3 and 7 years of age\n* Children who have had recent knee surgery\n\nExclusion Criteria:\n\n* Children older than 7\n* Children unable to cooperate with protocol steps","3 Years","7 Years",{"count":155,"type":22},5,[25],"The Investigators are investigating a continuous passive motion device to exercise the knee of young children with arthrogryposis after they have had knee surgery.",[159],"Arthrogryposis","NOT_YET_RECRUITING","2026-05-27",{"date":163,"type":37},"2026-05-29",{"date":93,"type":22},{"date":166,"type":22},"2027-06",{"name":43,"class":44},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":125,"sex":17,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":69},"100408479","role-of-body-composition-in-large-for-gestational-age-infants-lga-with-oral-feeding-difficulty-100408479","NCT04599010","Role of Body Composition in Large for Gestational Age Infants (LGA) With Oral Feeding Difficulty","Pilot Randomized Controlled Trial Comparing FFM-indexed Feeding vs. Standard Feeding in LGA Infants With Oral Feeding Difficulty and Disproportionate Body Composition.","Inclusion Criteria:\n\n* LGA infants with oral feeding difficulty born at ≥ 35 weeks gestation, with FM z-score \\> +1.0 in body composition measurement\n\nExclusion Criteria:\n\n* Infants on any respiratory support, Infants on enteral feeding duration \\> 60 minutes due to hypoglycemia concerns, videofluoroscopic swallow study (VFSS) demonstrating unsafe swallowing function, GI surgical conditions, significant neurological morbidities, and major congenital, genetic syndromes\u002Fanomalies","1 Week","10 Weeks",{"count":178,"type":22},40,[25],"Large for Gestational Age (LGA) infants have excess fat-mass (FM) proportion secondary to prolonged in utero exposure to an energy-rich environment. Our preliminary data suggest that excess FM proportion can be associated with oral feeding delay and a potentially modifiable therapeutic target to improve oral feeding outcomes. The objective of this study is to determine the impact of a short-term Fat-free mass (FFM)-indexed feeding on the oral intake volumes in LGA infants with oral feeding difficulties.",[182,183,184],"Body Composition","Feeding; Difficult, Newborn","Nutrition Disorder, Infant","2026-05-22",{"date":161,"type":37},{"date":188,"type":37},"2024-09-26",{"date":190,"type":22},"2027-12-31",{"name":43,"class":44},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":95},"100461082","non-invasive-functional-assessment-and-pathogenesis-of-morquio-a-100461082","NCT05284006","Non-invasive Functional Assessment and Pathogenesis of Morquio A","Non-invasive Functional Assessment and Pathogenesis of Morquio A (NIFAMA)","NIFAMA","Inclusion Criteria:\n\n* Patients affected by MPS IVA. The diagnosis of MPS IVA is confirmed by deficient enzyme activity of \\\u003C 5% of normal activity level as measured in plasma or leukocytes.\n\nExclusion Criteria:\n\n* No",{"count":201,"type":22},60,"OBSERVATIONAL","Morquio A disease is a devastating systemic skeletal disease in which detailed progression and pathogenesis remain unknown. The proposed project aims to establish a non-invasive objective assessment that can be applicable to all ages of patients to better understand the progress of their disease and the most serious clinical problems (cervical instability and stenosis, tracheal obstruction, hyperlaxity of joints, hip dysplasia, and small lung capacity). The outcome of this project will lead to a more precise understanding of the skeletal\u002Fpulmonary compromise and defining clinical endpoints in this disease for future clinical trials of current or developing therapies.",[205,206,207],"Mucopolysaccharidosis IV Type A","Morquio A Syndrome","MPS IVA",[209,210,211,212,213],"skeletal dysplasia","GALNS","keratan sulfate","tracheal narrowing","short stature","2026-05-11",{"date":216,"type":37},"2026-05-13",{"date":218,"type":37},"2021-05-01",{"date":220,"type":22},"2027-04-30",{"name":43,"class":44},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":95},"100588812","phase-3-characterization-of-bronchodilator-response-in-children-with-bronchiolitis-using-phenotypic-and-genotypic-features-100588812","NCT06946264","Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features","Inclusion Criteria:\n\n* Children between 3 to 24 months of age\n* Clinical diagnosis of bronchiolitis by the treating provider(s), defined by the American Academy of Pediatrics as a clinical syndrome involving lower respiratory tract symptoms\n* Children who either have no history of prematurity or have a history of prematurity but without associated co-morbidities\n* Emergency department (ED) visit to seek care at Nemours Children's Health-Florida (NCH-FL)\n\nExclusion Criteria:\n\n* Patients previously enrolled in the PI's K12 study\n* Documented history of asthma or reactive airway disease\n* Co-morbidities affecting airway response (e.g., chronic lung disease, bronchopulmonary dysplasia, bronchiectasis, congenital heart disease, immunodeficiency, neurologic condition)\n* Diagnosis of pneumonia by chest radiography\n* Inhaled, nebulized, or oral corticosteroid use within 72 hours of ED evaluation\n* Inhaled, nebulized, or oral bronchodilator administration within 4 hours of ED arrival","3 Months","24 Months",{"count":231,"type":22},400,[233],"PHASE3","Bronchiolitis is the leading cause of pediatric morbidity and healthcare costs. Despite the commonplace use of bronchodilator treatments, like albuterol, in conditions like asthma, their efficacy in bronchiolitis remains controversial due to the heterogeneity in patient response. Although studies indicate that bronchodilators do not enhance outcomes in bronchiolitis, meta-analyses can obscure the heterogeneity of treatment effects. While bronchodilator response genetics have not been explored in bronchiolitis, treatment effectiveness variations often depend on genomic factors. Genome-wide association studies (GWAS) have linked genetic variants with bronchodilator response and outcomes in childhood asthma, suggesting a bronchodilator-responsive genotype. This proposal aims to extend this paradigm to bronchiolitis, addressing the gap in knowledge where GWAS and clinical characteristics intersect. The proposed study's objective is to characterize phenotypic and genotypic variations of children with bronchiolitis and their association with bronchodilator response. We hypothesize that children with bronchiolitis who exhibit clinical and historical characteristics associated with atopy and specific physical findings have genetic variants linked to bronchodilator response. To achieve this, we propose to (Aim 1) define airway responsiveness to bronchodilator treatment in children with bronchiolitis using the change in respiratory score, (Aim 2a) identify the associations between candidate genetic variants and bronchodilator response among children with bronchiolitis, and (Aim 2b) determine the associations between candidate genetic variants and clinical patient data to identify bronchodilator-responsive children with bronchiolitis. A prospective, double-blind, randomized, placebo-controlled trial of a single albuterol dose in children aged 3 to 24 months presenting with bronchiolitis to the emergency department will be conducted to achieve these aims. Patient information and respiratory assessment outcomes will be collected before and after intervention. Blood, urine, DNA buccal swabs, and nasopharyngeal swabs will also be collected. Completion of these aims will result in a novel clinical prediction model for bronchodilator response determination in bronchiolitis, integrating clinical, physical, and genetic data. Furthermore, this research supports the candidates' career development goals of advancing training in clinical trial research design and execution and becoming an expert in clinical and translational methods to enhance pediatric emergency department health and outcomes. Ultimately, this work will inform an R01 application to validate an evidence-based prediction rule for identifying bronchodilator-responsive children with bronchiolitis through a multi-center emergency medicine research network, optimizing therapeutic approaches, and reducing resource use in those with a low likelihood of bronchodilator response.",[236,237],"Bronchiolitis","Bronchodilator Agents",[239],"double-blind randomized clinical trial","2026-05-06",{"date":242,"type":37},"2026-05-08",{"date":244,"type":37},"2022-07-08",{"date":246,"type":22},"2030-12-31",{"name":43,"class":44},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":254,"maxAge":54,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":145},"100609746","sanctuary-farm-prescription-in-adolescents-100609746","NCT07218588","Sanctuary Farm Prescription in Adolescents","Inclusion\n\n1. Patients seen at Nemours TJU Primary Care Clinic\n2. Ages 12-17 years at enrollment\n3. BMI \\> or = 85th percentile\n4. English Speaking\n5. Willing to provide parental permission and ability to provide child assent for the study\n\nExclusion\n\n1. Children with neurocognitive delays that would limit participation or ability to assent\n2. Use of G-tube\u002FJ-tube\n3. Food allergies that in the opinion of the investigators would interfere with ability to participate.","12 Years",{"count":256,"type":22},50,[25],"The goal of this research study is to learn if an 8-week produce prescription program (in partnership with a local urban farm) can increase fruit and vegetable consumption in overweight teens and improve their blood pressure and weight. The main questions are:\n\n* Is a produce prescription program in overweight teens feasible?\n* Will a produce prescription with educational videos increase weekly fruit and vegetable intake?\n* Will a produce prescription with educational videos improve blood pressure and weight for height?\n\nResearchers will compare the teens' fruit and vegetable intake, blood pressure and weight for height before and after the produce prescription. Researchers will also see how feasible it is by measuring the number of produce prescriptions are picked up by the families and how many educational videos are viewed.\n\nParticipants will:\n\n* complete questionnaires related to their diet and nutrition\n* measure their blood pressure and weight at the beginning and end of the study\n* obtain weekly produce prescriptions",[260,261],"Obesity &Amp; Overweight","Adolescence",[263,264,265,266],"adolescence","obesity","overweight","diet","2026-05-04",{"date":242,"type":37},{"date":270,"type":37},"2025-11-20",{"date":272,"type":22},"2026-07-31",{"name":43,"class":44},{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":125,"sex":17,"minAge":281,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":95},"100547342","detection-of-vocal-fold-motion-impairment-on-noninvasive-positive-pressure-100547342","NCT06406725","Detection of Vocal Fold Motion Impairment on Noninvasive Positive Pressure","Point-of-Care Ultrasound to Detect Vocal Fold Motion Impairment on Pediatric Patients on Noninvasive Positive Pressure Ventilation","Inclusion Criteria:\n\n* Age 0 to 18 years\n* Scheduled to receive a fiberoptic nasolaryngoscopy with the otolaryngology team to assess for vocal fold motion impairment\n* Status post great vessel, esophageal, or tracheal surgery that could disrupt the recurrent laryngeal nerve\n\nExclusion Criteria:\n\n* Tracheostomy in place\n* Age \\>18 years\n* History of vocal cord paralysis\u002Fparesis\n* Patients who cannot have their neck placed in a neutral or slightly extended position due to injury or ligament laxity","1 Day","18 Years",{"count":256,"type":22},"The goal of this prospective, observational study is to evaluate for the presence of vocal fold motion impairment (VFMI) in the children admitted to the pediatric intensive care unit on noninvasive positive pressure ventilation (NIV PPV). Participants will have two ultrasounds of their vocal folds performed, once while on NIV PPV and once after weaned off of the NIV PPV. This results of these scans will be reviewed against one another and against the gold standard, fiberoptic nasolaryngoscopy (FNL). The main question this study aims to answer is: Can POCUS be used to reliably detect VFMI while pediatric patients on supported with NIV PPV?",[286,287,288,289,290],"Vocal Cord Dysfunction","Vocal Cord Paralysis","Vocal Cord Paresis","Recurrent Laryngeal Nerve Palsy","Recurrent Laryngeal Nerve Injuries","2026-04-30",{"date":240,"type":37},{"date":294,"type":37},"2024-03-30",{"date":296,"type":22},"2028-05-30",{"name":43,"class":44},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":152,"maxAge":282,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":95},"100635444","phase-4-a-clinical-trial-on-the-use-of-lidocaine-infusion-during-surgery-for-pediatric-upper-extremity-fractures-and-its-impact-on-total-perioperative-opioid-requirements-100635444","NCT07552766","A Clinical Trial on the Use of Lidocaine Infusion During Surgery for Pediatric Upper Extremity Fractures and Its Impact on Total Perioperative Opioid Requirements","A Prospective, Randomized, Double-blind Trial of the Impact of Intraoperative Intravenous Lidocaine Infusion on Total Opioid Requirements in Children Undergoing Surgical Fixation of Upper Extremity Long Bone Fractures Under General Anesthesia","Inclusion Criteria:\n\n* Patients aged 3-18 years\n* Patients \\> 10 kg\n* Patients who present to Nemours Children's Hospital - Delaware Valley (NCH-DE) for surgical fixation of upper extremity fractures from distal humerus to distal radius\n\nExclusion Criteria:\n\n* Children \\\u003C 3 years or \\> 18 years\n* Patients with allergy to local anesthetics\n* Patients who are eligible for an receive a peripheral nerve block\n* Patients with multi-trauma or open fractures\n* Patients with previous history of seizure disorder\n* Patients with conduction abnormalities or cardiac arrhythmia requiring chronic treatment\n* Patients on strong CYP450 inhibitors (fluvoxamine, erythromycin, ciprofloxacin, rifampin, allopurinol, ketoconazole, itraconazole)\n* Patients with chronic kidney or liver dysfunction\n* Patients with planned use of continuous infusion pain medications (opioids, ketamine, alpha-2- agonists)\n* Patients with positive pregnancy test prior to surgery or nursing mothers\n* Patients who parents decline enrollment",{"count":306,"type":22},90,[308],"PHASE4","This study is a prospective, randomized, double-blind clinical trial evaluating whether intraoperative intravenous lidocaine infusion (IVLI) reduces opioid requirements and improves postoperative pain control in children undergoing surgical fixation of upper extremity long bone fractures under general anesthesia. Ninety pediatric patients, ages 3-18 will be enrolled and randomized 1:1 to receive either IV lidocaine or placebo (normal saline) during surgery.\n\nAll participants will receive standardized anesthesia care and postoperative pain management. Opioid consumption and pain scores will be measured intraoperatively and throughout the postoperative recovery, with the primary outcome focused on total opioid use 60 minutes after arrival to the post-anesthesia care unit (PACU). Secondary outcomes include opioid use at additional time points, postoperative pain scores, PACU length of stay, rescue antiemetic use and the relationship between infusion duration and outcomes.\n\nPatients will be closely monitored for signs of local anesthetic systemic toxicity and other adverse events. The goal of this study is to determine whether IV lidocaine is an effective opioid-sparing adjunct in pediatric orthopedic surgery and to support safer, multimodal analgesia strategies.",[311,312,313,314,315,316,317],"Fracture Arm","Fracture Closed of Lower End of Forearm, Unspecified","Fracture Elbow","Fracture Fixation","Fracture Fixation, Internal","Fracture Forearm","Fracture Distal Radius","2026-04-22",{"date":320,"type":37},"2026-04-27",{"date":322,"type":22},"2026-05",{"date":324,"type":22},"2029-07",{"name":43,"class":44},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":333,"maxAge":54,"enrollmentInfo":334,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":347,"locationsCount":69},"100504547","breaking-disparities-in-access-to-advanced-diabetes-technologies-in-children-with-type-1-diabetes-100504547","NCT05849753","Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes","Breaking Health Care Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes","Inclusion Criteria:\n\nDiagnosis of T1D for at least 1 year based on clinical presentation (polyuria, polydipsia, weight loss, and\u002For ketoacidosis, or with positive diabetes autoantibodies) on insulin, including injections or open-loop pumps\n\n* HbA1C ≥ 8.0% at least twice within the last 12 months before study initiation, upper limit of HbA1C \\\u003C14%\n* Be of lower SES, defined based on \\\u003C 200% above published US levels of poverty by family size and income, or based on exceptional circumstantial needs in the opinion of the investigators\n* Approximately 1\u002F3 AA, 1\u002F3 Hispanic\u002FLatinos, 1\u002F3 non-Hispanic whites. Asians, Pacific Islanders and other ethnic groups however will not be excluded from participation if other criteria met\n* History of hypothyroidism on adequate replacement therapy with normal thyroid function will be allowed\n\nExclusion Criteria:\n\n* Severe eczema or any other skin condition that would limit availability of healthy skin to wear devices\n* Chronic medications\u002Fmedical conditions that could interfere with diabetes management (ADHD medications allowed)\n* Chronic seizures, or severe neurodevelopmental delay\n* Current use of hybrid closed-loop, automated insulin delivery system\n* Significant mental health disorder that in opinion of the investigator would hinder device use","6 Years",{"count":256,"type":22},"50 children\u002Fadolescents (ages 6 to \\\u003C18yrs) with T1D in suboptimal control (HbA1c≥8.0%) and lower SES (below 200% poverty line) on insulin therapy (either injections or open-loop pumps) will be recruited at Nemours \\~ 1\u002F3 each AA, Hispanic\u002FLatino, non-Hispanic whites. All families that qualify and agree to transition to closed-loop technologies will be recruited to allow data to be gathered before and after use of devices. They will go through the process of approval with the assistance of an insurance navigator in clinic. Those not a CGM will be prescribed one as well. Diabetes care will be 'real life', devices will be prescribed, and care per clinic routine with periodic device downloads. Principal outcome, time-in-range, will be analyzed at 3-months compared to baseline, each participant their own control. Secondary outcomes including HbA1c, other glucose metrics and questionnaires related to use of technology and diabetes distress will be also analyzed. All outcomes will also be collected at 6-months. Results could have important and fast applicability to the field and help better inform decision makers, including payers, clinicians, and patients and families and could serve to decrease health care disparities in this needy population.",[337,338,339,340],"Diabetes Mellitus, Type 1","Child","Delivery of Health Care","Equipment and Supplies","2026-02-19",{"date":343,"type":37},"2026-02-23",{"date":345,"type":37},"2023-07-26",{"date":143,"type":22},{"name":43,"class":44},{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":125,"sex":17,"minAge":4,"maxAge":282,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":358,"conditions":359,"keywords":367,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":95},"100609243","the-utilization-of-ultrasound-to-diagnose-pediatric-elbow-fractures-100609243","NCT07212036","The Utilization of Ultrasound to Diagnose Pediatric Elbow Fractures","The Utilization of Ultrasound to Diagnose Pediatric Elbow Fractures: Evaluation of Cost Savings, Radiation Exposure, and Patient Satisfaction","Inclusion Criteria:\n\n• Pediatric patient with elbow pain\n\nExclusion Criteria:\n\n* Polytrauma (more than one injury)\n* Deformity of the arm including the elbow\n* Pain in any other location than the elbow\n* Pain in other parts of the same limb including the, wrist, forearm, shoulder, hand\n* Pain in other limbs,\n* Puckering of the skin (skin indentation)\n* Obvious fracture\n* Open wound at or around the elbow\n* Pain and swelling without trauma\n* Concerns for tumor or infection\n* Suspected nursemaid's elbow",{"count":356,"type":22},225,[25],"The goal of this intervention trial is to learn if a ultrasound diagnosis of elbow fractures can improve care in pediatric patients seen in the emergency room. The main questions it aims to answer are:\n\nThe primary outcomes measured are cost of the emergency visit, radiation exposure, time spent in the emergency department and patient satisfaction.\n\nPatients who are evaluated with ultrasounds of the elbow will be compared to patients who have x-rays of the elbow.\n\nParticipants will be assigned either to the ultrasound group or x-rays group when they present with elbow pain.",[360,361,362,363,364,365,366],"Elbow Pain","Supracondylar Humerus Fracture","Radial Head Fractures","Radial Head or Neck Fractures","Elbow Dislocation","Humerus Fractures","Jakob II Classification",[368,369,370,371,372,373,374,375,376,377,378,379],"elbow pain","elbow fracture","supracondylar humerus fracture","pediatric","lateral humeral condyle fracture","radial head fracture","radial neck fracture","monteggia fracture","elbow dislocation","radial head dislocation","emergency department","ultrasound","2026-01-27",{"date":382,"type":37},"2026-01-29",{"date":384,"type":37},"2025-07-22",{"date":386,"type":22},"2027-09-02",{"name":43,"class":44},{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":17,"minAge":395,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":408,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":423,"locationsCount":95},"100604834","evaluation-of-the-auryzon-ear-20-system-in-ear-reconstruction-100604834","NCT07154667","Evaluation of the Auryzon™ EAR 2.0 System in Ear Reconstruction","Enhancing Cartilaginous Ear Reconstruction - An Institutional Outcomes Study","Inclusion Criteria:\n\n* Patients aged 5-20 years seeking to undergo surgical ear reconstruction or microtia repair under general anesthesia through NCH-FL\n* Pre-existing physical deformity of the ear necessitating surgical reconstruction\n* Patient of sufficient health to undergo surgery under general anesthesia\n* Parental or legally acceptable representative (LAR) permission obtained for inclusion in the study; patient assent obtained where age-appropriate\n* Sufficient fluency in English or Spanish to complete patient\u002Fparent surveys\n\nExclusion Criteria:\n\n* Patients who will be ≤4 years old, or ≥21 years old at time of surgery\n* Patients with ear deformities do not require surgical correction\n* Patient's whose ear reconstruction surgery will be performed somewhere other than Nemours Children's Hospital - Florida\n* Patients determined to be in poor health to undergo surgery under general anesthesia\n* Parental or LAR permission cannot be obtained, and\u002For patient of sufficient age and cognitive capacity declines to assent\n* Lack of fluency in English or Spanish to complete patient\u002Fparent surveys","5 Years","20 Years",{"count":80,"type":22},[25],"This study aims to improve surgical outcomes for children and young adults with ear differences severe secondary to congenital conditions (like microtia, a condition where the ear is underdeveloped), trauma (such as dog bites), or surgical resections secondary to skin cancer. The investigators have developed a novel medical device to shape cartilage into pre-determined shapes that, once assembled, assists the surgeon in creating an anatomically accurate cartilaginous ear framework, reduce surgery time, and minimize wire need. Other factors that might affect the quality of surgical outcomes will be examined in clinical trial participants.",[401,402,403,404,405,406,407],"Microtia, Congenital","Microtia","Microtia-Anotia","Ear Deformities, Acquired","Ear Deformity External","Ear Malformation","Ear Cartilage",[409,410,411,412,413,414,415,416],"microtia","ear reconstruction","craniofacial difference","anotia","plastic surgery","ear defect","ear trauma","ear deficit","2025-12-19",{"date":419,"type":37},"2025-12-29",{"date":421,"type":37},"2025-10-01",{"date":246,"type":22},{"name":43,"class":44},{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":17,"minAge":431,"maxAge":282,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":439,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":447,"locationsCount":95},"100469034","cgm-and-lifestyle-changes-in-patients-with-impaired-glucose-tolerance-100469034","NCT05387551","CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance","Effect of Adding Continuous Glucose Monitoring (CGM) to Lifestyle Changes on Insulin Sensitivity in Patients With Impaired Glucose Tolerance","Inclusion Criteria:\n\n1. Children 10 to \\\u003C18 years old (i.e., before their 18th birthday)\n2. Impaired glucose tolerance based on standardized oral glucose tolerance test (OGTT) or fasting glucose per American Diabetes Association criteria,\n3. Overweight or obese (BMI ≥85th percentile for age\u002Fsex)\n4. Patients are pubertal, defined as females with breast Tanner stage II or above, or males with testicular volume ≥4 mL\n\nExclusion Criteria:\n\n1. Existing diagnosis of type 1 or type 2 diabetes\n2. Prepubertal\n3. Taking medications that affect insulin sensitivity (e.g.,chronic corticosteroids whether systemic or inhaled). Metformin allowed if stable dose.\n4. Patients and\u002For families not willing to wear the CGM for the duration of the study period or lack of compliance after recruitment","10 Years",{"count":433,"type":22},15,[25],"The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood\u002Fadolescence and adulthood.",[437,438],"Impaired Glucose Tolerance","Prediabetes",[440,264,441],"impaired glucose tolerance","adolescents",{"date":443,"type":37},"2025-11-26",{"date":445,"type":37},"2022-12-01",{"date":93,"type":22},{"name":43,"class":44},{"id":449,"slug":4,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":17,"minAge":395,"maxAge":54,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":95},"100500101","NCT05791877","Non-Invasive Measurement of Pulmonary Dysfunction in Children With Cerebral Palsy","Inclusion Criteria:\n\n* Subjects should have cerebral palsy a GMFCS levels IV, V\n\nExclusion Criteria:\n\n\\-",{"count":454,"type":22},250,[25],"This proposal addresses pulmonary dysfunction in severe cerebral palsy by using a novel non-invasive respiratory sensor. The two aims of the project are to 1) provide a screening tool to detect respiratory distress and 2) Find a correlation between the degree of pulmonary dysfunction and scoliosis in children with cerebral palsy.",[458],"Cerebral Palsy","2025-11-19",{"date":461,"type":37},"2025-11-24",{"date":463,"type":37},"2023-10-02",{"date":465,"type":22},"2026-11",{"name":43,"class":44},{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":125,"sex":17,"minAge":473,"maxAge":54,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":95},"100274346","non-invasive-respiratory-monitor-100274346","NCT02851043","Non-Invasive Respiratory Monitor","Inclusion Criteria:\n\n* Healthy volunteers\n* Neuromuscular disease subjects with mild breathing difficulty\n* Capable of following verbal instructions\n\nExclusion Criteria:\n\n* Severe breathing difficulties","11 Years",{"count":475,"type":22},20,[25],"This study will clinically evaluate a newly developed respiratory monitor - pneuRIP. The pneuRIP uses Respiratory Inductance Plethysmography (RIP) bands to measure key breathing indices non-invasively. This study compares the pneuRIP to an existing Respitrace system (Carefusion, Yorba Linda CA). 10 normal children and 10 children with breathing difficulties will be monitored with both systems.",[479,480],"Neuromuscular Diseases","Healthy Volunteers",{"date":482,"type":37},"2025-11-21",{"date":484,"type":37},"2014-08",{"date":93,"type":22},{"name":43,"class":44},{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":17,"minAge":431,"maxAge":493,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":507,"leadSponsor":509,"locationsCount":95},"100547334","pilot-trial-assessing-the-effectiveness-of-laser-hair-depilation-on-pilonidal-disease-recurrence-in-patients-with-darker-skin-color-100547334","NCT06406621","Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker Skin Color","Inclusion Criteria:\n\n* Age: 10-21 years\n* Diagnosis of pilonidal disease\n* Fitzpatrick skin type IV, V, or VI\n\nExclusion Criteria:\n\n* History of photosensitivity\n* Actively inflamed pilonidal sinus (will be offered enrollment upon resolution).","21 Years",{"count":495,"type":22},36,[25],"Pilot randomized trial assessing the effectiveness of laser hair depilation on pilonidal disease recurrence in patients with darker skin color",[499],"Pilonidal Disease",[501,502],"laser hair depilation","pilonidal","2025-10-22",{"date":505,"type":37},"2025-10-24",{"date":421,"type":37},{"date":508,"type":22},"2027-09-30",{"name":43,"class":44},{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":517,"targetDuration":395,"studyType":202,"phases":4,"briefSummary":519,"conditions":520,"keywords":528,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":95},"100406187","primordial-dwarfism-registry-100406187","NCT04569149","Primordial Dwarfism Registry","Primordial Dwarfism Registry at Nemours Children's Hospital, Delaware","Inclusion Criteria:\n\n* Individuals with MOPDII, Meier-Gorlin syndrome, IMAGe syndrome, RNU4atac-opathies (MOPDI\u002FIII, Roifman syndrome, Lowry-Wood syndrome), LIG4 syndrome, and other classified as well as unclassified types of microcephalic primordial dwarfism and related conditions, as diagnosed by a medical provider, are eligible for this registry.\n\nExclusion Criteria:\n\n* individuals without microcephalic primordial dwarfism or closely related conditions",{"count":518,"type":22},200,"The goal of this registry is to collect information on individuals with forms of microcephalic primordial dwarfism as well as related conditions. The study team hopes to learn more about these conditions and improve the care of people with them by establishing this registry.",[521,522,523,524,525,526,527],"MOPDII","Meier-Gorlin Syndrome","Saul-Wilson Syndrome","Microcephalic Primordial Dwarfism","IMAGe Syndrome","RNU4atac-opathy (e.g MOPDI, Lowry-Wood Syndrome, and Roifman Syndrome)","LIG4 Syndrome",[529],"microcephalic primordial dwarfism","2025-09-25",{"date":421,"type":37},{"date":533,"type":37},"2008-03-11",{"date":535,"type":22},"2030-01-01",{"name":43,"class":44},{"id":538,"slug":539,"hasResults":11,"nctId":540,"briefTitle":541,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":543,"minAge":254,"maxAge":282,"enrollmentInfo":544,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":545,"conditions":546,"keywords":549,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":560,"locationsCount":95},"100605946","effects-of-glucagon-like-peptide-1-glp-1-agonist-in-neuro-reproductive-function-in-obese-adolescent-females-with-polycystic-ovary-syndrome-pcos-100605946","NCT07169136","Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)","Inclusion Criteria:\n\n* Diagnosed with PCOS, by NIH criteria: oligomenorrhea (menstrual cycles \\\u003C21 or \\>35 days) and hyperandrogenism (testosterone level or free androgen index (FAI) \\> refence range for tanner stage) and in good overall health\n* Obesity (equal to or more than the 95th percentile)\n* Females ages 12 to 18 years, at least 2 years post-menarche\n* Participants has persistent symptoms of PCOS and obesity despite lifestyle modifications for at least 4 months.\n\nExclusion Criteria:\n\n* Has abnormal thyroid function tests at Screening.\n* Has suspected or known Diabetes mellitus, impaired fasting glucose, or elevated hemoglobin A1c.\n* Has non-classic congenital adrenal hyperplasia.\n* Has hyperprolactinemia.\n* Has a known history or family history of medullary thyroid carcinoma or MEN2 and history of pancreatitis\n* Participants receiving prior treatment with metformin, GLP-1 agonists, oral contraception pills, progesterone, or other insulin sensitizers for at least 6 weeks prior to Screening.\n* Is currently pregnant or has been pregnant.","FEMALE",{"count":475,"type":22},"The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and\u002For ethnic minorities. Normal puberty onset and progression is dependent on normal hypothalamic-pituitary-gonadal (HPG) axis which is affected by whole body metabolism. Gonadotropin-releasing hormone (GnRH) and gonadotropins, LH and FSH, are released in a pulsatile manner for appropriate sex steroids production and gonadal function. Proper pulsatility in the GnRH system is disrupted by a significant change in energy balance such as in obesity. Polycystic Ovary Syndrome (PCOS) is the most common neuroendocrine dysfunction in women of reproductive age. Glucagon-like peptide-1 (GL-1), a peptide hormone secreted by the intestinal enteroendocrine L-cells following glucose and fat intake, stimulates insulin release by the pancreas in response to glucose, decreases gastric emptying and inhibits glucagon secretion. GLP-1 receptors are present in the hypothalamic nuclei and pituitary gland; and it is thought that GLP-1 may directly stimulate GnRH secretion and partially regulate reproduction. In animal studies, GLP-1 was found to stimulate GnRH secretion, to regulate kisspeptin (Kiss-1) mRNA and GnRH mRAN expression. GLP-1 receptor agonists are FDA-approved to treat adults and adolescents with obesity. Although the impact of GLP-1 receptor agonists in reproductive health has been investigated in preclinical trials, and in men with obesity and functional hypogonadism, no studies to date have investigated the impact of GLP-1 receptor agonists in female neuroendocrine function, particularly in youth. The goal of this proposal is to gather critical preliminary data to investigate, in a group of obese adolescent females with PCOS, the impact of GLP-1 agonist administration in addition to lifestyle modifications on the neuroendocrine rhythms - LH frequency and amplitude (principal); body composition, adiposity; and carbohydrate metabolism and insulin sensitivity. To accomplish these aims, we will recruit a cohort of up to 20 adolescents ages 12-18 years, at least 2 years post-menarche, with obesity, PCOS, by NIH criteria, without carbohydrate intolerance and in otherwise good health. Research volunteers will be advised on lifestyle modifications of diet and exercise as per routine, and a GLP-1 agonist will be started according to the product's label as per FDA guidelines in children with obesity. Medication will be titrated to maximal therapeutic dose, as per routine clinical practice. Participants will be treated for a total of 16 weeks. Neuroendocrine rhythms pre- and post-treatment will be compared.",[547,548],"Polycystic Ovarian Syndrome in Adolescent Females","Obesity (Disorder)",[550,551,552,553],"PCOS","Obesity","Adolescent Female","irregular menstrual cycles","2025-09-15",{"date":556,"type":37},"2025-09-16",{"date":558,"type":37},"2025-09-11",{"date":93,"type":22},{"name":43,"class":44},{"id":562,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":564,"briefSummary":26,"conditions":565,"keywords":566,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":571,"leadSponsor":573,"locationsCount":45},"100534583",{"count":21,"type":22},[25],[28,29],[28,31,32],"2025-07-08",{"date":569,"type":37},"2025-07-11",{"date":39,"type":37},{"date":572,"type":22},"2026-12-30",{"name":43,"class":44},{"id":575,"slug":576,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":581,"targetDuration":395,"studyType":202,"phases":4,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":591,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":595,"locationsCount":95},"100406188","rhizomelic-chondrodysplasia-punctata-registry-100406188","NCT04569162","Rhizomelic Chondrodysplasia Punctata Registry","Rhizomelic Chondrodysplasia Punctata Registry at Nemours Children's Health","Inclusion Criteria:\n\n* Diagnosed with RCDP or closely related conditions by metabolic and\u002For genetic testing\n\nExclusion Criteria:\n\n* Not meeting diagnosis of RCDP or closely related conditions by study team physician review of prior metabolic and\u002For genetic testing",{"count":582,"type":22},100,"The goal of this registry is to collect medical information on individuals with rhizomelic chondrodysplasia punctata and closely related conditions. The study team hopes to learn more about these conditions and improve the care of people with it by establishing this registry.",[585,586,587,588,589,590],"RCDP - Rhizomelic Chondrodysplasia Punctata","RCDP1","RCDP2","RCDP3","RCDP4","RCDP5",{"date":569,"type":37},{"date":593,"type":37},"2013-05-17",{"date":535,"type":22},{"name":43,"class":44},{"id":597,"slug":4,"hasResults":11,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":11,"sex":17,"minAge":603,"maxAge":604,"enrollmentInfo":605,"targetDuration":4,"studyType":23,"phases":607,"briefSummary":608,"conditions":609,"keywords":612,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":45},"100338099","NCT03682042","Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up","A Cluster Randomized Clinical Trial of Umbilical Cord Milking Versus Early Cord Clamping on Short and Long-term Outcomes in Neonates Who Are Non-Vigorous at Birth","CORDMILK-FU","Inclusion Criteria:\n\n* Enrolled in CORDMILK trial\n* Non-vigorous at birth\n\nExclusion Criteria:\n\n* None","22 Months","26 Months",{"count":606,"type":22},3442,[25],"An extension of the CORDMILK trial, the CORDMILK follow-up trial will evaluate the neurodevelopmental outcomes at 22-26 months age of term\u002Flate preterm infants who were non-vigorous at birth and received umbilical cord milking (UCM) or early cord clamping (ECC).",[610,611],"Hypoxic-Ischemic Encephalopathy","Birth Asphyxia",[32],"2025-07-07",{"date":615,"type":37},"2025-07-10",{"date":617,"type":37},"2022-10-17",{"date":619,"type":22},"2027-10-30",{"name":43,"class":44},""]